ABM-168

N/A

Report date: 2023/08/22 09:25:50
NME

Base Information

Drug NameABM-168
Drug Alias NameABM-168
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinaseDual specificity mitogen-activated protein kinase kinase 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesABM Therapeutics
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMosaica MedicinesBichen (Shanghai) Pharmaceutical Technology Co Ltd
Inactive CompaniesABM Therapeutics
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A